Shanghai-based cell therapy biotech nabs new funds; Colorado biotech nets an acquisition
A Lilly Asia Ventures-backed cell therapy biotech has secured $50 million in Series A funds to bankroll CAR-NK therapies.
At the helm of the Shanghai …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
